[Immunogenic cell death in hematological malignancies].
[Rinsho ketsueki] The Japanese journal of clinical hematology(2021)
Abstract
Anticancer therapies using cytotoxic drugs, which had been considered to be immunosuppressive, could induce immunogenic cell death (ICD) in cancer cells. Anticancer drugs, tumor-lytic viruses, and radiation therapies can establish long-term immune memory via emmision of damage-associated molecular pattern from cancer cells, activating the acquired immunity. This phenomenon could prolong the survival of patients with cancer. ICD was originally reported in solid tumors; however, recent studies have shown that it also occurs in hematological malignancy. Several studies have been trying to combine ICD inducers and other immunotherapies, such as CAR-T-cell therapy. Therefore, treatment strategies should be considered based on drugs' ability to evoke ICD.
MoreTranslated text
Key words
Damage-associated molecular patterns,Immunogenic cell death,Leukemia,Myeloma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined